Skip to main content

Centene Reaffirms 2026 Outlook and Redeems Debt Notes

Tipranks - Wed Mar 11, 5:38AM CDT

Claim 70% Off TipRanks Premium

Centene ( (CNC) ) has issued an update.

Centene said it will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, where it expects to reaffirm its 2026 full-year GAAP diluted EPS guidance of more than $1.98 and adjusted diluted EPS of more than $3.00, highlighting its reliance on non-GAAP metrics to reflect core operating performance. The company also disclosed that on March 10, 2026, it delivered a notice of partial redemption for $1 billion of its 4.25% notes due December 15, 2027, to be redeemed on March 25, 2026, leaving about $1.19 billion outstanding and signaling ongoing balance sheet and capital structure management.

The most recent analyst rating on (CNC) stock is a Hold with a $42.00 price target. To see the full list of analyst forecasts on Centene stock, see the CNC Stock Forecast page.

Spark’s Take on CNC Stock

According to Spark, TipRanks’ AI Analyst, CNC is a Neutral.

The score is held down primarily by the TTM earnings and margin deterioration and a bearish technical setup (price below key moving averages with negative MACD). These are partially offset by stronger TTM cash flow and a more optimistic 2026 outlook from management (EPS > $3 with targeted HBR/SG&A improvement), though marketplace and medical-cost headwinds keep execution risk elevated.

To see Spark’s full report on CNC stock, click here.

More about Centene

Centene Corporation is a healthcare enterprise focused on managed care programs, providing health insurance and related services primarily to under-insured and uninsured individuals through government-sponsored programs and other health plans. The company serves a broad range of beneficiaries in the U.S. healthcare market and positions itself as a key player in publicly funded healthcare coverage.

Average Trading Volume: 6,013,023

Technical Sentiment Signal: Hold

Current Market Cap: $21.3B

See more data about CNC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.